乳腺癌中度大分割放疗中皮肤微生物组、炎症与皮肤毒性的关联
结果显示放疗期间患侧乳房致病性Finegoldia、Dermacoccus和Variovorax丰度增加,Variovorax减少而Staphylococcus增加与临床医生报告和患者报告的皮肤毒性相关,血浆干扰素γ与皮肤微生物组变化相关。
要点
- 放疗期间患侧乳房Finegoldia(P=.001)、Dermacoccus(P=.01)、Variovorax(P=.003)丰度增加。
- Variovorax减少而Staphylococcus增加与临床医生报告的2级瘙痒(P=.002)和皮炎(P=.012)相关。
- 上述微生物变化亦与患者报告中度或重度皮肤变暗(P=.002)和皮肤瘙痒(P=.012)相关。
核心结论
- 本研究显示在耐受良好的中度大分割乳腺放疗期间皮肤微生物组发生变化。
- 治疗后皮肤微生物组向基线恢复似乎与临床医生报告和患者报告的皮肤毒性改善相关。
研究设计与样本
- 于放疗前基线(T1)、放疗第1周(T2)、放疗第3周(T3)及放疗后3个月(T4)从患侧与对侧健康乳房共采集240份皮肤微生物组拭子和120份血浆样本。
- 皮肤微生物组标本采用16S V1-V3测序处理。
主要发现
- 放疗期间(T2和T3)患侧乳房皮肤微生物组与放疗前基线(T1)及对侧健康乳房存在差异。
- 放疗期间患侧乳房致病性Finegoldia(P=.001)、Dermacoccus(P=.01)和Variovorax(P=.003)丰度增加。
- 纵向分析显示Variovorax减少而Staphylococcus增加与临床医生报告的2级瘙痒(P=.002)和皮炎(P=.012)增加相关。
- 上述变化亦与患者报告中度或重度皮肤变暗(P=.002)和皮肤瘙痒(P=.012)增加相关。
- 血浆干扰素γ与接受放疗的乳腺癌女性皮肤微生物组变化相关。
关键数值与推荐
- 放疗期间患侧乳房Finegoldia丰度增加(P=.001)。
- 放疗期间患侧乳房Dermacoccus丰度增加(P=.01)。
- 放疗期间患侧乳房Variovorax丰度增加(P=.003)。
- Variovorax减少而Staphylococcus增加与临床医生报告的2级瘙痒相关(P=.002)。
- Variovorax减少而Staphylococcus增加与患者报告中度或重度皮肤变暗(P=.002)和皮肤瘙痒(P=.012)相关。
临床怎么用
- 在频繁处方的中度大分割全乳放疗中观察到的高级别毒性较少。
- 皮肤微生物组变化可能作为症状缓解或干预的进一步靶点,随着超大分割疗程变得更常见。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Up to 95% of women during and after radiation therapy (RT) for breast cancer have reported cutaneous toxicity. However, the biologic link between skin microbiome and skin toxicities from RT remains largely unknown. This study aimed to assess the associations of skin microbiome with clinician- and patient-reported skin toxicities and inflammatory markers in women with breast cancer receiving RT. METHODS AND MATERIALS: A prospective, longitudinal study was conducted at a single institution. Thirty-two women with breast cancer undergoing moderately hypofractionated RT for 3 to 4 weeks after breast conserving surgery were enrolled and 30 of them were analyzed. A total of 240 swabs for skin microbiome and 120 plasma samples were collected pre-RT baseline (T1), week-1 of RT (T2), week-3 of RT (T3), and 3 months post-RT (T4), from the cancer-affected and contralateral healthy breasts. Skin microbiome specimens were processed using 16S V1-V3 sequencing. RESULTS: Differences in skin microbiome of the treated breasts during RT (T2 and T3) were observed compared with the skin microbiome of pre-RT baseline breasts (T1) and contralateral, healthy breasts, with the affected breasts having an increased abundance of pathogenetic Finegoldia (P = .001), Dermacoccus (P = .01), and Variovorax (P = .003) during RT. Longitudinal analysis showed that decreased Variovorax but increased Staphylococcus were associated with increased clinician-reported grade 2 pruritus (P = .002) and dermatitis (P = .012), and increased patient-reported moderate or severe darkened skin (P = .002) and itchy skin (P = .012). Additionally, the plasma interferon gamma was associated with changes in skin microbiome in women with breast cancer undergoing RT. CONCLUSIONS: This study shows changes in the skin microbiome during well-tolerated moderately hypofractionated breast RT. The skin microbiome return toward baseline appears to associate with improvement of clinician- and patient-reported skin toxicities post-treatment. Although there were few high-grade toxicities observed among frequently prescribed courses of hypofractionated whole breast RT, changes in skin microbiome may be of interest as further targets of symptomatic relief or intervention as ultrahypofractionated courses become more common.
引用
- Bai J, Gong C, Hu YJ, et al. Skin Microbiome, Inflammation, and Skin Toxicities in Women With Breast Cancer Receiving Moderately Hypofractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 40058710. doi:10.1016/j.ijrobp.2025.02.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。